MMP19 and metabolic dysfunction-associated steatotic liver disease: Although RASi use generally did not show a significant reduction for NAFLD progression risk in men or women regardless of the dose and duration, women who were prescribed a mean daily RASi dose of 0.5 or more, but less than one, revealed a significantly lower aOR of 0.492 (95% CI 0.259–0.935).